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Abstract
Background: shRNA-mediated lethality screening is a useful tool to identify essential targets in cancer biology.
Ovarian cancer (OC) is extremely heterogeneous and most cases are advanced stages at diagnosis. OC has a high
response rate initially, but becomes resistant to standard chemotherapy. We previously employed high throughput
global shRNA sensitization screens to identify NF-kB related pathways. Here, we re-analyzed our previous shRNA
screens in an unbiased manner to identify clinically applicable molecular targets.
Methods: We proceeded with siRNA lethality screening using the top 55 genes in an expanded set of 6 OC cell
lines. We investigated clinical relevance of candidate targets in The Cancer Genome Atlas OC dataset. To move
these findings towards the clinic, we chose four pharmacological inhibitors to recapitulate the top siRNA effects:
Oxozeaenol (for MAP3K7/TAK1), BI6727 (PLK1), MK1775 (WEE1), and Lapatinib (ERBB2). Cytotoxic effects were
measured by cellular viability assay, as single agents and in 2-way combinations. Co-treatments were evaluated in
either sequential or simultaneous exposure to drug for short term and extended periods to simulate different
treatment strategies.
Results: Loss-of-function shRNA screens followed by short-term siRNA validation screens identified therapeutic
targets in OC cells. Candidate genes were dysregulated in a subset of TCGA OCs although the alterations of these
genes showed no statistical significance to overall survival. Pharmacological inhibitors such as Oxozeaenol, BI6727,
and MK1775 showed cytotoxic effects in OC cells regardless of cisplatin responsiveness, while all OC cells tested
were cytostatic to Lapatinib. Co-treatment with BI6727 and MK1775 at sub-lethal concentrations was equally potent
to BI6727 alone at lethal concentrations without cellular re-growth after the drugs were washed off, suggesting the
co-inhibition at reduced dosages may be more efficacious than maximal single-agent cytotoxic concentrations.
Conclusions: Loss-of-function screen followed by in vitro target validation using chemical inhibitors identified
clinically relevant targets. This approach has the potential to systematically refine therapeutic strategies in OC. These
molecular target-driven strategies may provide additional therapeutic options for women whose tumors have
become refractory to standard chemotherapy.
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Background
Ovarian cancer is the most aggressive gynecological ma-
lignancy among women with more than 20,000 new
cases and nearly 15,000 deaths per year in the USA. At
diagnosis, most women have advanced disease stage gen-
erally due to the lack of signs and symptoms at early
stages. The current standard care includes surgical
cytoreduction followed by platinum- and taxane-based
chemotherapy. Initial cytotoxic chemotherapy effectively
achieves complete response in most cases, but relapse
within 18 months is common and eventually leading to
chemotherapy failure. Therefore, new therapeutic strat-
egies are necessary to improve treatment of recurrent
chemotherapy-resistant tumors.
One of the reasons for the high recurrence rate may
be the heterogeneity of ovarian cancer. Ovarian cancer
can be classified as four major histological subtypes in-
cluding serous, endometrioid, mucinous, and clear cell
and they are believed to be different diseases sharing the
same final anatomical location [1]. High grade serous
ovarian cancer (HGSOC) is most common and accounts
for most deaths in women with ovarian cancers. HGSOC
was further classified as mesenchymal, immunoreactive,
differentiated, and proliferative based on molecular and
genetic profiles [2]. It is characterized by high genomic
instability with frequent DNA copy number gains and
losses and moderate load of mutations [3]. Advances in
understanding molecular aberrations and their patho-
logical signaling have facilitated the use of molecular-
driven targeted therapies, and the NCI-MATCH (Mo-
lecular Analysis for Therapy Choice) clinical trial has
been launched to evaluate the effectiveness of cancer
treatment according to molecular abnormalities.
Loss-of function screens by shRNA/siRNA provide a
useful tool to identify novel therapeutic targets in the la-
boratory. For example, a recent synthetic lethality screen
suggested a mechanistic explanation of mutual exclusiv-
ity between CCNE1 amplification and BRCA1/2 muta-
tion, and further showed the sensitivity of CCNE1-
amplified tumor cells to bortezomib [4]. Another in vivo
shRNA screen identified BRD4 as a therapeutic target,
demonstrating that BRD4 inhibitor (JQ1) decreased sur-
vival of high MYC-expressing ovarian cancer cells [5].
We previously performed two independent shRNA
screens to investigate the functional role of NF-kB sig-
naling in ovarian cancer cell proliferation and survival
[6, 7]. In one of these screens, CHEK1 loss sensitized
ovarian cancer cells to IKKε loss [6]. We proceeded to
evaluate the combined efficacy of CHEK1 inhibitor with
topotecan, a salvage treatment for platinum-resistant
ovarian cancer, showing a synergistic cytotoxic effect
with reduced dosages of both drugs [8]. These results
suggest that molecular-based therapy may improve the
efficacy of currently available treatments, while possibly
reducing side effects by lowering the effective concentra-
tion required to achieve tumor response.
In the current study, we re-focused our efforts to iden-
tify targets essential for OC survival, independent of NF-
kB. Herein we show our prioritization strategy from
shRNA screens, further evaluation by siRNA knock-
down and chemical inhibitors, and recommended com-




Stock solutions of 50 mM Lapatinib (GW572016)
Ditosylate (Selleck, S10128), 10 mM MK1775 (Selleck,
S1525), 10 mM BI6727 (Selleck, S2235), and 10 mM
Oxozeaenol (Tocris, cat. no 3604) were prepared in
DMSO except 5 mM Cisplatin (Tocris, cat no 2251)
in PBS, and aliquots were stored at −80 °C. The high-
est final concentration of DMSO in the culture in this
study was 0.1 % which caused no cellular toxicity in
ovarian cancer cells. All working stocks were diluted
in complete medium.
Cell lines
All ovarian cancer cell lines in this study were previously
described including the source and authentication of the
cell lines, and maintained in RPMI supplemented with
10 % heat-inactivated FBS [9].
The cancer genome atlas data
TCGA ovarian cancer dataset was analyzed and extracted
using a web-based tool (http://www.cbioportal.org/public-
portal/).
Validation screen by siRNAs
All siRNAs were purchased from Qiagen, and their IDs,
sequences and plate layout were shown in Additional
file 1: Table S1. For each cell line, seeding cell num-
ber and lipid volume were determined for optimal
transfection efficiency. Cells were seeded at 750 cells/
well except Skov3 at 500 cells/well, and transfected
with 0.06 μl RNAiMax except Skov3 with 0.07 μl.
siRNA transfection was performed at a final concen-
tration of 20 nM, and 2 μl of 400 nM stock siRNAs
were spotted on 384 well plates. These spotted siRNA
plates were stored at −80 °C until used. Twenty μl of
serum free RPMI containing RNAiMax was added and
plates were incubated at room temperature for 15 min
followed by adding cells re-suspended in 20 μl of RPMI
containing 20 % FBS. The plates were then incubated at
room temperature for 30 min before putting at 37 °C.
Ovcar8, Ovcar3, Skov3, and Igrov1 cells for 3 days, A2780
for 2 days, and Ovcar5 cells were incubated for 4 days
allowing approximately two doubling times for optimal
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cellular viability assays. The screening in each cell line was
independently repeated in three plates. AllStars Neg. con-
trol siRNA from Qiagen (cat # 1027281) was used as a
negative control (siNeg) and AllStars Hs Cell Death Con-
trol siRNA (cat # 1027299) was used as a positive control.
Cellular viability was determined using CellTiter Glo
(20 μl/well) and the average viability from three plates was
normalized by the average of siNeg from each plate.
Viability assay
Cells were seeded in 96-well plates at a density of 1–
2000 cells/50 μl/well in triplicates. In general, the drug
in 50 μl was added 24 h after seeding and XTT assay
was routinely performed in 3 days after drug treatment
unless indicated. Cellular viability was assessed by incu-
bating cultures with 25 μl of XTT freshly mixed with
PMS (Sigma) and absorbances were read in a Tecan
plate reader (Research Triangle Park, NC). Cellular pro-
liferation was calculated relative to experimental nega-
tive controls and standard deviation was calculated from
triplicates. Based on XTT numbers, IC50s were calcu-
lated using CompuSyn software [10]. Briefly, the median
effect dose (Dm) is obtained from the anti-log of the x-
intercept of the median effect plot: log(Fa/Fu) =
m*log(D) - m*log(Dm) where Fa is Fraction affected, Fu
is Fraction unaffected, m is slope [11]. Viability assay in
SCM (stem cell media) was done using CellTiter Glo Lu-
minescent Cell Viability Assay according to manufac-
turer’s instructions (Promega).
Western blot analysis
Total protein was extracted from sub-confluent cells
with 1 % NP40 lysis buffer containing 150 mM NaCl,
50 mM TrisHCl, 10 % glycerol, 1 X Halt proteinase in-
hibitor cocktail, 5 mM NaF, and 1 mM NaOrthovana-
date. Protein concentrations were estimated using BCA
Protein Assay Kit (Thermo Scientific, Rockford, IL). The
proteins were separated on the NuPage 4–12 % gel (Invi-
trogen, Carlsbad, CA) and the band was visualized using
either Luminata Classico or Crescendo Western HRP
substrate system (Millipore) depending on the signal in-
tensities. Antibodies c-ErbB2/c-Neu (Calbiochem, cat.
no. OP15L), WEE1 (Santa Cruz, sc-5285), PLK1 (Milli-
pore, #05-844), TAK1 (Santa Cruz, sc-166562), and
GAPDH (Millipore, MAB374) were used, and the sec-
ondary antibodies ECL anti-rabbit IgG HRP and ECL
anti-mouse IgG HRP (GE Healthcare) were used at
1:5000 dilutions.
Flow cytometry analysis
Ovcar5 and Ovcar8 cells were grown for 1 week in the
presence of traditional RPMI culture media containing
10 % FBS or in serum-free stem cell media containing
20 ng/ml EGF and 10 ng/ml FGF. Cultures were
maintained for 7 days (with media change at day 3) be-
fore performing flow cytometry. Approximately 5 × 105
cells were analyzed for ALDH activity and CD133 expres-
sion. ALDH activity was evaluated using the Aldefluor Kit
(StemCell Technologies) according to manufacturer’s in-
structions. Following staining procedure for ALDH, cells
were incubated with APC conjugated CD133 antibody
(Miltenyi Biotec) 1:11 in the Aldefluor assay buffer for
30 min on ice protected from light.
Statistical analysis
Statistical analysis for Fig. 2a was performed using the
Mann-Whitney U test in IBM SPSS Statistics Version
21. Cellular viability for each siRNA construct in each of
the six cell lines was compared to that with siNeg in
triplicate experiments; p < 0.05 was considered statisti-
cally significant. Error bars represent the standard error
of the mean. For Fig. 2b, shRNA counts for a given
shRNA in a given experiment were normalized within
an experiment by pool and then fitted with a negative bi-
nomial extension of the Poisson distribution, with pa-
rameters fitted iteratively with the mean estimate via
maximum likelihood and the method of moments used
to estimate the dispersion [12]. P-values for differences
between experiments were found by comparing the log
of the estimated normalized averages between experi-
ments with a normal approximation to the error. In
comparing an experiment where a given shRNA had 0
counts across all replicates resulting in an infinite esti-
mate of the log average, the p-value reported was the
likelihood of getting 0 counts across all replicates given
the negative binomial model of the shRNA in the experi-
ment to which it was being compared. Statistical analysis
for Fig. 5a–e was performed using the One-Way
ANOVA test with a Tukey post-hoc test in IBM Statis-
tics Version 21. Relative cellular viability of each experi-
mental condition was compared to control; p < 0.05 was
considered statistically significant. Error bars represent
the standard deviation of the mean.
Results
Re-analysis of shRNA-mediated lethality screens identified
55 kinases essential for OC survival
Our previous lethality screenings were performed in
Ovcar5 and A2780 using shRNA library directed against
the human kinome [6], and in Ovcar3 and Igrov1 using
whole genome shRNA library [7] in the context of NF-
kB signaling. In the current study, we reanalyzed these
data from four different cell lines in an unbiased manner
to identify genes required for OC survival. In each cell
line, comparisons were made at two different time
points relative to Day 0, and candidate shRNAs were
selected if identified in both comparisons with a p value
of less than 0.05 and a fold change of less than 0.7. With
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this cut-off, 305 (240 genes), 253 (205 genes), 190 (174
genes), and 404 (325 genes) shRNAs were selected in
A2780 (Additional file 2: Table S3), Ovcar5 (Additional
file 3: Table S4), Igrov1 (Additional file 4: Table S5), and
Ovcar3 (Additional file 5: Table S6), respectively. Under
the most stringent cut-off of four out of four cell lines,
five genes including GUCY2F, MKNK2, PDK3, PIK3AP1,
and WEE1 were identified as essential for OC cell
survival (Fig. 1a). When the stringency of analysis was
relaxed to allow three out of four cell lines affected, a
total of 55 genes were included. The most significant
cellular functions regulated by these 55 genes were cell
cycle, and cancer cell death and survival, as determined
by Ingenuity Pathway Analysis (Fig. 1b). Next, we exam-
ined the expression levels of these 55 genes in OCs in
The Cancer Genome Atlas (TCGA) to estimate clinical
a
b
Fig. 1 Re-analysis of shRNA screens in an unbiased manner a Target genes from shRNA screens in four cell lines are compared and common
targets are shown in venn diagram. b Fifty five genes are uploaded onto Ingenuity Pathway Analysis and the most significant network is shown
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relevance associated with their expression [2]. Fourteen
genes were overexpressed with a cut-off of log2 ratio
greater than 0.5 in more than 40 % of the tumors com-
pared to nine normal controls, while 11 genes were
interestingly underexpressed with a cut-off of log2 ratio
less than −0.5 in more than 40 % of tumors (Table 1).
Although it seems unreasonable to see that overexpres-
sion and underexpression of a gene would produce simi-
lar phenotype, this might be due to the perturbation of
physiological balance by either overexpression or under-
expression of each gene, contributing to tumorigenesis.
Of note, TCGA dataset consists of ovarian serous adeno-
carcinoma, and our candidate genes were identified from
two serous (Ovcar5 and Ovcar3) and two non-serous
(A2780 and Igrov1) cell lines. With this in mind, we fur-
ther validated the functional significance of these 55
genes by a short-term knockdown using siRNA.
siRNA-mediated validation identified pro-survival essential
targets in OC cancer lines
We hypothesized that if the targets could be validated by
different methods and in multiple cell lines, in spite of
the extremely heterogeneous genetic backgrounds, it
would be stronger and have more widely applicable
values in ovarian cancer. In order to validate and
prioritize candidate genes, we compared the effect of
target suppression by shRNA (long term stable loss),
siRNA (short term acute and transient loss), and then
chemical inhibitors. We employed siRNA lethality assay
in an expanded set of 6 OC cell lines additionally
including Ovcar8 (serous) and Skov3 (non-serous). Two
siRNAs per gene were tested in a 384-well format as
outlined (Additional file 1: Table S1). Transient transfec-
tion protocols such as seeding cell numbers and lipid to
siRNA ratio were optimized in each cell line using posi-
tive (AllStars Hs Cell Death Control) and negative (All-
Stars siNeg. control) siRNA controls (Additional file 6:
Figure S1). siRNA screen in each cell line was done in
three independent plates rather than three replicates in
one plate. This resulted in bigger standard deviations in
general, but this design would minimize false positives.
We selected targets with below 0.95 of the average de-
creased viabilities of two siRNAs compared to siNeg
control from the three independent replicates in all 6
OC cell lines (Additional file 7: Table S7). Based on
these criteria, six genes (EPHB1, FER, MAP3K7, PLK1,
ERBB2, and WEE1) were identified in all six cell lines
(Fig. 2a). Cellular viability for the selected siRNA con-
structs in each of the six cell lines was statistically sig-
nificantly decreased as compared to siNeg (Additional
file 7: Table S7). Of note, analysis of both constructs on
individual cell lines reached statistical significance in the
majority of cases. Since the 55 candidate targets were se-
lected based on a three out of four cell line criteria in
shRNA screens, it was not surprising to observe no sig-
nificant lethal effects in some cell lines in these siRNA
screens. The degree of cytotoxicity of knockdown was
greater by shRNA than by siRNA in general, possibly
due to stable selection of shRNA, although this was not
always true for every gene in each cell line such as
shPLK1 in Igrov1 (Fig. 2b). Regardless of OC subtypes
(serous vs. non-serous) or the status of p53, the loss of
PLK1 or WEE1 was generally more detrimental than
that of the other genes. In TCGA dataset, the number of
individuals with alterations in each gene was small, and
their alterations had no statistically significant associ-
ation with overall survival (Fig. 2c, d). Additionally, over-
all survival analysis of each gene alone did not produce a
statistically significant association either.
Pharmacological inhibitors generally recapitulated siRNA
lethality
To move these findings towards the clinic, we investi-
gated whether pharmacological inhibitors could re-
semble the lethal effect of the loss-of function by
siRNA. We chose four inhibitors: oxozeaenol (for
MAP3K7/TAK1), lapatinib (ERBB2), MK1775 (WEE1),
and BI6727 (PLK1) based on the availability of
pharmacological compounds and clinical applicability.
We measured cell sensitivity to inhibitor in a 3-day
assay (Fig. 3a–d). The ranges of IC50s were 0.6–
6 μM, 120–610 nM, and 10–35 nM for oxozeaenol,
MK1775, and BI6727, respectively (Fig. 3e, Additional
file 8: Figure S2). Interestingly, all cell lines were
Table 1 The percentage of ovarian cancer tumors in TCGA are
shown with a cut-off of log2 tumor/normal ratio in more than
40 % tumors detected by Agilent G4502A microarray chips
Gene Log2 > 0.5 Gene Log2 < −0.5
ALPK2 54 % CSNK1G2 63 %
AURKA 97 % DDR2 80 %
BUB1B 96 % GUCY2F 97 %
CDC7 89 % ITK 50 %
EPHB1 67 % LRRK2 92 %
GRK6 44 % MGC42105 46 %
KSR2 41 % MKNK2 46 %
MAP3K7 45 % PDGFRB 49 %
NEK2 97 % PRKCB 61 %
NLK 59 % RET 41 %




The data shown are from the dataset of Nature publication [2]. The data were
extracted from TCGA analysis with RMA normalized log2 ratio of tumor to nine
normal controls
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cytostatic to lapatinib, including ERBB2-amplified
Skov3, suggesting that a kinase independent function
of ERBB2 may play a role in OC cell survival. Since
lapatinib also inhibits EGFR, we double-checked the
shRNA data to see the effect of stable knockdown of
EGFR in all four cell lines (Ovcar3, Igrov1, Ovcar5,
and A2780) and found that shEGFR did not affect the





Fig. 2 Validation of shRNA candidate genes by siRNAs in six ovarian cancer cell lines a siRNA screens are done in three serous (S) and three non-
serous (NS) cell lines. p53 status is indicated; Ovcar3 (Mut: P72R, R248Q), Ovcar8 (Mut: amino acid deletion: aa126-132), Igrov1 (Mut: Y126C), Ovcar5
and Skov3 (Null, no p53 detected on Western blot), A2780 (wide type) [6]. The value of each siRNA from CellTiter Glo assay was normalized by
the average value of siNeg in each plate to calculate relative cellular viability, and then the average of three normalized values were plotted with
standard deviation. The red bar is drawn at 1.0 which means no toxicity upon knockdown. Cellular viability for each siRNA construct across the six
cell lines was compared to that with siNeg; * indicates p < 0.05 (Mann Whitney U-test). Error bars represent the standard error of the mean for
each cell line, per siRNA. b Target shRNA depletion (shown as fold change: FC) at two different time points compared to day 0 (baseline control)
are shown. shRNA screens were done in four biological replicates in Ovcar5 and A2780, and in six biological replicates in Ovcar3 and Igrov1 [6, 7].
p-value compares the log of the estimated normalized averages between experiments (see methods). c Genetic alterations of six candidate targets
were examined in TCGA ovarian tumor samples with sequencing and CNA data using a web-based cBioPortal tool (http://www.cbioportal.org/public-
portal/). d Overall survival analysis based on the alterations of six candidate targets in OC was extracted from TCGA data analysis
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study. This suggests that EGFR may not facilitate cellular
viability, at least in these cell lines. The steady-state level
of each target protein varied across cell lines (Fig. 3f).
Interestingly, ERBB2 expression was detected in only
Igrov1 and Skov3. OC cells showed different levels of
WEE1 expression presenting no clear correlation with the
sensitivity to MK1775, while they showed abundant ex-
pressions of TAK1 and PLK1 and were sensitive to oxo-
zeaenol and BI6727. Taken together, inhibitors of PLK1,
TAK1, and WEE1 were potent in killing OC cells, consist-
ent with the siRNA findings. In addition, OC subtypes
(serous or non-serous) or the steady-state levels of
target proteins could not predict the sensitivities to
these inhibitors.
Cisplatin-resistant cells or stem-like population are sensitive
to PLK1 inhibition
OC initially responds to platinum chemotherapy treat-
ment, but most cancers eventually relapse and become
resistant to standard agents including cisplatin. In the
current study, we found that most cell lines highly
express PLK1 protein, and the PLK1 inhibitor BI6727
potently killed OC cell lines (Fig. 3d and f). Therefore,
we tested whether BI6727 would sensitize cisplatin re-
sistant OC cells. We first examined the cytotoxicity of
cisplatin in a panel of 7 OC cell lines, and observed that
Ovcar8, Skov3, and HeyA8 were relatively resistant to
cisplatin with IC50s of greater than 1 μM (Fig. 4a,
Additional file 9: Figure S3). When combined with
BI6727, cisplatin did not enhance the cytotoxicity of
BI6727 except at high concentrations if any (Fig. 4b).
PEO1 and PEO4 are a pair of high grade serous OC
cell lines established from the same patient before
and after platinum-based chemotherapy [13]. We
found that PEO1 was very sensitive to single treat-
ment of either drug alone, while PEO4 was resistant
to cisplatin. Of note, cisplatin attenuated the cytotox-




Fig. 3 Evaluation of cellular toxicities upon pharmacological intervention a–d Cells were seeded at 1000 cells/well in 50 μl, 20–24 h prior to the
addition of the drug in 50 μl. XTT assay was performed 3 days later upon drug treatment. The viability was calculated relative to no drug
treatment and the error bars represent standard deviations calculated from three replicates. e IC50 values were calculated by CompuSyn after
converting relative viability values to fraction affected numbers. f The steady-state level of each inhibitor target protein was examined by Western
blotting analysis. Total 40 μg of proteins was separated on 4–12 % gradient gel and GAPDH was used as a loading control
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Fig. 4 (See legend on next page.)
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that combining BI6727 with cisplatin to treat cisplatin
resistant OC patients may not be clinically beneficial.
Cisplatin-resistant cells have the ability to re-populate
tumors and cause disease recurrence. We hypothesized
that PLK1 inhibitor BI6727 could reduce the tumor-
initiating cell population due to its ability to kill
cisplatin-resistant cells. We attempted to enrich for
this tumor-initiating or cisplatin resistant cell popula-
tion by culturing Ovcar5 and Ovcar8 cell lines in
stem cell medium (SCM) [14, 15]. CD133 expression
and/or ALDH1 activity are potential markers of the
stem-like population [15–18]. OC cell lines in SCM
showed statistically significant increases in CD133
(Ovcar5) or ALDH (Ovcar8) positive population from
three to four independent experiments (Fig. 4c). As
expected, Ovcar8 cells were slightly more resistant to
cisplatin when cultured in SCM, while both cell lines
showed similar sensitivity to BI6727 in both condi-
tions, with a trend towards increased sensitivity in
the SCM condition (Fig. 4d, Additional file 10: Figure
S4). This suggests that BI6727 is potent to kill cells
independent of cisplatin responsiveness and may be
effective in stem-like population.
Combined inhibition at low concentrations killed OC cells
more effectively than single treatment at high
concentrations
Single agent therapies often result in resistance and re-
lapse, and combination treatments may have a higher
chance of success with a better therapeutic index. WEE1
and PLK1 are involved in the G2/M phase of cell cycle
regulation, and TAK1 is an upstream activator of the
tumor-promoting NF-kB signaling. We hypothesized
that combined kinase inhibition, either within one path-
way or targeting independent pathways, may provide
more potent cellular cytotoxicity than single agents
alone. We proceeded to test the cytotoxic effect of
WEE1 and PLK1 inhibitors, by measuring cellular viabil-
ities after exposing cells to low concentrations of the
drug pair in six cell lines (Fig. 5a, Additional file 11:
Figure S5A). Concentrations were chosen to be below
the IC50 of each compound when administered as a
single agent (see Fig. 3). In general, the combination
of inhibitors killed more cells than single drug in all
six cell lines, but the effect was somewhat dependent
on cell line. Cellular viability with single drug treat-
ment was compared to either no treatment or dual
treatment, and was found to be statistically signifi-
cantly different (p < 0.05, two-way ANOVA test with a
Dunnett post-hoc test). Importantly, the combination
effectively killed cisplatin resistant cell lines such as
Ovcar8 and Skov3.
Since BI6727 and MK1775 are currently under clinical
development, we further focused on these PLK1 and
WEE1 inhibitors to examine the benefit of their com-
bined treatment over an extended time period. We
treated cells at sub-lethal (IC50) and lethal (IC80) con-
centrations either once or twice in different orders as in-
dicated (Fig. 5b, c). At day 7, the culture medium was
removed and replaced with fresh complete medium. Cel-
lular re-growth upon drug withdrawal was measured at
days 11 and 14. Exposing cells to a single dose of the co-
treatment or two doses of single treatment at sub-lethal
concentrations allowed subsequent re-growth of cancer
cells when the drugs were no longer present (Fig. 5b, c,
left panel, Additional file 11: Figure S5B, 5D). Interest-
ingly, the cells treated with MK1775 were recovered
more quickly than those with BI6727. At lethal single-
agent concentrations, single dose of either drug still
showed cellular re-growth, but twice treatments with
BI6727 or BI6727/MK1775 in either order prevented re-
growth (Fig. 5b, c, right panel, Additional file 11: Figure
S5C, 5E). Interestingly, two doses of MK1775 treatment
initially achieved maximal cytotoxicity, but the cellular
viability recovered after the drug was washed off. Most
importantly, twice co-treatments with BI6727 and
MK1775 at sub-lethal concentrations achieved maximal
cytotoxic activities and the cells did not grow back after
the drugs were washed off. Taken together, this result
provides a strong rationale to combine these two drugs
although the combination was not synergistic in all ovar-
ian cancer cell lines tested. In summary, these data sug-
gest that the combined treatment with BI6727 and
MK1775 at sub-lethal concentrations may be efficacious
(See figure on previous page.)
Fig. 4 Cytotoxic effect of BI6727 in the presence of cisplatin a Cells were seeded at 1000 cells/well in 50 μl, 20–24 h prior to the addition of the
drug in 50 μl. XTT assay was performed 3 days later upon drug treatment. The viability was calculated relative to no drug treatment and the error
bars represent standard error calculated from three replicates. b XTT assays were performed as described in Fig. 4a except using two inhibitors of
Cisplatin and BI6727 in 50 μl. PEO1 and PEO4 were seeded at 2000 cells per well. c CD133 surface expression and ALDH1 activity were measured
by flow cytometry in Ovcar5 and Ovcar8 cells grown in either RPMI or SCM. The data are compiled from 4 (for Ovcar5) and 3 (for Ovcar8)
independent experiments. For statistical analysis, the differences in positive population of markers were calculated by 2-tailed t-test d Ovcar5 and
Ovcar8 cells (2 × 103 cells/well) were seeded on white plates in RPMI media containing 10 % FBS or in serum-free stem cell media containing
20 ng/ml EGF and 10 ng/ml FGF. Twenty-four hours after seeding, cells were treated with cisplatin or BI6727. The viability was measured using
the CellTiter Glo and calculated relative to no drug treatment and the error bars represent standard error calculated from three experiments. * p < 0.05
by one-way ANOVA with Tukey post-hoc test. T (trend), p≤ 0.2
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Fig. 5 Cytotoxicity of different combination treatments a Cells were seeded at 2000 cells/well in 50 μl, 20–24 h prior to the addition of the drug
in 50 μl. XTT assay was performed 3 days later upon drug treatments of PLK1 and TAK1 inhibitors. Statistical comparisons were calculated using two-way
ANOVA with Dunnett post-hoc test, and p< 0.05 considered significant. All experimental conditions resulted in statistically significant differences from
no-treatment control, except for MK alone in OVCAR5, indicated by ns. b, c OVCAR8 cells (b) or OVCAR5 cells (c) were seeded at 1000 cells/well in 50 μl.
First drug was added in a 50 μl volume and then second drug was added in a 80 μl volume producing the indicated final drug concentration after
removing 80 μl from each well. For days 7 and 14 time point plates, 150 μl of fresh complete medium was added after taking 150 μl of old culture. At
Day11, fresh medium was added to day 14 plates in the same way. Of note, the cellular viabilities of untreated cells at days 11 and 14 were saturated and
might not be accurately reflect in these graphs. The charts display compiled data from three independent experiments. For b and c, n indicates non-
significant difference (p> 0.05) compared to no treatment, based on the Two-Way ANOVA test with a Dunnett post-hoc test
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to treat ovarian cancer, achieving reduced toxicities and
avoiding recurrence.
Discussion
By re-analyzing our previous shRNA screens, we identi-
fied 55 genes required for ovarian cancer survival. Not
surprisingly, these genes are known to regulate cell cycle,
cell death and survival. Their pro-survival functions
were validated by siRNA-mediated depletion in a
panel of ovarian cancer cell lines representing differ-
ent histologies. While the shRNA screens were per-
formed over 1–2 weeks with stable knockdown, the
siRNA validation screens were carried out by transi-
ent transfection over about two cellular doubling
times. Therefore, the validated targets by siRNA de-
pletion are likely to be involved in direct and imme-
diate cellular survival role. Among those genes, we
focused on ERBB2, TAK1, WEE1, and PLK1 based on
clinical application and availability of pharmacological
inhibitors. Consistent with our findings, PLK1 was
also identified in a recent in vivo shRNA screen in
ovarian cancer [5].
Despite successful OC cell killing with siRNA knock-
down of ERBB2, the ERBB2 inhibitor lapatinib showed
very limited cellular toxicity. It is unclear why the gene
knockdown was so effective, when protein expression
was negligible in most cell lines. We used the monoclo-
nal antibody produced against a c-terminal synthetic
peptide (Calbiochem, OP15L) to measure the protein,
leaving the possibility that even cells without detectable
expression may express different isoforms on which they
depend for survival. It is also possible that ERBB2 iso-
forms function in a kinase independent manner in ovar-
ian cancer cells. In either case, selection of ERBB2
inhibitor for treatment of ovarian cancer should not be
based solely on its level of gene expression. Also, a re-
cent clinical study agrees with our finding, showing that
lapatinib had a minimal activity and only a small fraction
of ovarian cancer overexpressed EGFR and ERBB2
(HER2) [19].
Consistent with our siRNA data, the MAP3K7/TAK1
inhibitor oxozeaenol was toxic to OC cell lines in the
range of 1–5 μM. TAK1 can act as an upstream regula-
tor of the NF-kB signaling promoting ovarian cancer
growth and metastasis [20]. Although this chemical in-
hibitor is a selective and potent inhibitor of TAK1, its
use is limited to preclinical in vitro and in vivo models.
On the other hand, the WEE1 inhibitor MK1775 has
been actively tested in leukemia and many solid tumors
including ovarian cancer as mono- or combined therapy
(clinicaltrials.gov). For example, MK1775 is currently
under evaluation in combination with either gemcitabine
or paclitaxel and carboplatin to treat refractory or
resistant ovarian cancer or platinum-sensitive p53 mu-
tated ovarian cancer.
PLK1 inhibitor, BI6727 (volasertib) is currently regis-
tered in 20 different clinical trials, and one study in
ovarian cancer has been completed (NCT01121406). In
this trial, none of patients in the volasertib arm com-
pleted the treatment course due to progressive disease
or adverse effects. Another clinical trial (NCT00969761)
using BI6727 in combination with either cisplatin or
carboplatin in advanced and metastatic solid tumors
is completed, but the study reports are not yet avail-
able. Based on our preclinical in vitro data, combin-
ing BI6727 with cisplatin did not result in additional
cytotoxicity, and the combination was even possibly
antagonistic in platinum-resistant PEO4 cells. These
results provide a potential explanation as to why the
prior clinical trial was unsuccessful. On the other
hand, the combination of BI6727 with WEE1 inhibitor
MK1775 resulted in cytotoxic activity at concentra-
tions lower than those required to kill cells as single
agents. Furthermore, the combined effect was main-
tained even after the drugs were washed off. These
findings support moving forward with combined
WEE1/PLK1 inhibition as a promising new clinical
strategy for the treatment of women with platinum-
refractory ovarian cancer.
Clinical benefit for women with relapsed platinum re-
fractory or resistant ovarian cancer is typically defined as
objective response or disease stabilization for greater
than 6 months. These criteria are typical endpoints in
phase two trials testing potential new therapies for
women recurrent ovarian cancer [21]. Numerous drugs
have been tested in the setting of platinum-resistant
ovarian cancer but unfortunately response rates achieved
were less than 6–20 % with short duration of responses
(12–17 weeks). While it is difficult to extrapolate
from in vitro tumor cell line suppression to long term
clinical benefit in patients, the lack of tumor cell re-
growth after combined PLK1 and WEE1 inhibition in
our study suggest that this could be an interesting
strategy to develop further. Another consideration for
clinical development is the occurrence of side effects
in patients. Again, while it is difficult to predict clin-
ical toxicity based on in vitro studies, it is likely that
lower doses of drugs would minimize side effects. In
our study, the sequential exposure of low-dose com-
bined drugs achieved similar tumor cell control as
higher doses. This suggests an effective and tolerable
treatment regimen to develop for women with re-
lapsed ovarian cancer.
Conclusions
Loss-of-function screens followed by in vitro target
validation using chemical inhibitors identified clinically
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relevant targets for ovarian cancer. This approach has the
potential to systematically refine therapeutic strategies for
treating a deadly disease. Molecular target-driven strat-
egies may provide additional therapeutic options for
women whose tumors have become refractory to standard
chemotherapy.
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